PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY)
announced on Tuesday that the FDA had approved Kevzara, also known as sarilumab,
for treating patients weighing 63 kg or more with active polyarticular juvenile
idiopathic arthritis or pJIA, a type of arthritis affecting multiple joints
simultaneously.

The approval is based on data from studies and pharmacokinetic information from
adults with rheumatoid arthritis, along with a study on pediatric pJIA patients
to determine dosage, effects, and safety.

Common adverse reactions in pJIA patients treated with Kevzara included
nasopharyngitis, neutropenia, upper respiratory tract infection, and redness at
the injection site.

Apart from pJIA, Kevzara is currently authorized in 25 countries for managing
moderately to severely active rheumatoid arthritis.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX